While Pfizer, Eli Lilly, J&J, GlaxoSmithKline and Sanofi-Aventis face expiring patents and a sizeable drop in rank in the coming years, Roche might hold strong and is poised to carry about 6 percent of the global prescription drug market in 2014. Ranked fifth in 2007, the company is also less at risk of losing revenue to genetic competitors. Report [1]